• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    6/17/24 12:31:43 PM ET
    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday's regular session. The company's market cap stands at $14.9 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 62.17% to $5.66. The company's market cap stands at $3.2 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares increased by 32.33% to $0.14. The market value of their outstanding shares is at $2.3 million.
    • Trxade Health (NASDAQ:MEDS) stock increased by 31.87% to $8.7. The company's market cap stands at $12.2 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock increased by 24.11% to $1.92. The company's market cap stands at $1.8 million.
    • Mirum Pharmaceuticals (NASDAQ:MIRM) shares moved upwards by 20.79% to $31.31. The company's market cap stands at $1.4 billion.

    Losers

    • Aerovate Therapeutics (NASDAQ:AVTE) shares declined by 93.4% to $1.62 during Monday's regular session. The company's market cap stands at $46.7 million.
    • Ovid Therapeutics (NASDAQ:OVID) stock fell 69.0% to $1.02. The market value of their outstanding shares is at $72.3 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares declined by 24.71% to $0.38. The company's market cap stands at $1.1 million.
    • Cara Therapeutics (NASDAQ:CARA) stock fell 22.12% to $0.27. The company's market cap stands at $14.9 million.
    • Evaxion Biotech (NASDAQ:EVAX) stock declined by 20.81% to $2.46. The market value of their outstanding shares is at $13.2 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) shares fell 20.71% to $0.41. The company's market cap stands at $48.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $ATRA
    $AVTE
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Mirum Pharmaceuticals Inc.
    $MIRM
    2/18/2026$130.00Outperform
    RBC Capital Mkts
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Ovid Therapeutics Inc.
    $OVID
    12/11/2025$3.00Buy
    Roth Capital
    Ovid Therapeutics Inc.
    $OVID
    11/17/2025Outperform
    Leerink Partners
    Ovid Therapeutics Inc.
    $OVID
    10/9/2025$7.00Outperform
    Oppenheimer
    Mirum Pharmaceuticals Inc.
    $MIRM
    9/24/2025$95.00Buy
    TD Cowen
    Mirum Pharmaceuticals Inc.
    $MIRM
    8/11/2025$89.00Buy
    Stifel
    More analyst ratings

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Notice to convene Evaxion's Annual General Meeting

    COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET. The meeting will be held at the company's offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. The agenda and proposals can be found on Evaxion's website, along with other materials: www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/ Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96 [email protected] About Evaxion Evaxion is a pione

    3/19/26 9:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

    JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

    3/19/26 7:50:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

    The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures and an open-label, proof-of-concept studyExpanding OV329 development to complementary indications in tuberous sclerosis complex seizures and infantile spasms, supported by a $60.0 million private placementOV4071, a first-in-class, oral KCC2 direct activator, received Human Research Ethics Committee approval and acknowledgement of its Clinical Trial Notification from the Australian Therapeutic Goods Administration, triggering a 30-day exercise period for the Company's outstandin

    3/18/26 6:05:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Mirum Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $130.00

    2/18/26 7:54:16 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    SEC Filings

    View All

    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

    6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    3/19/26 10:08:08 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:10:04 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:00:05 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:13:18 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:12:04 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:11:27 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

    For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

    2/21/25 11:48:20 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J acquired 159,277 shares and bought $8,999,984 worth of shares (131,425 units at $68.48) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    1/27/26 4:14:26 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Financials

    Live finance-specific insights

    View All

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

    - 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for

    2/25/26 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 6:01:44 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ATNF
    $ATRA
    $AVTE
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care